Slow CMO revenue growth could impact US
Dose contract manufacturing organisations (CMOs) had slow revenue growth in 2019, a trend continuing into 2020 that could impact the US.
List view / Grid view
News
GSK sets goals of net zero impact on environment by 2030
GSK will use 100 percent renewable electricity usage among other efforts in its plans to have a net zero impact on the climate by 2030.
CVnCoV COVID-19 vaccine safely elicits immune response in Phase I testing
The interim Phase I data suggests CVnCoV can safely induce a neutralising antibody response similar to that of convalescent COVID-19 patients with two 12μg vaccine doses.
Pharma M&A activity up 17 percent year-on-year in H1 of 2020
A new report has highlighted that despite the pandemic, pharma M&A activity rose but deal value fell in the first half of 2020.
Novel gelatin microcarrier developed to enhance cell production
Researchers who developed the dissolvable microcarrier for large-scale cell production and expansion say it offers higher yield and cost-effectiveness compared to traditional methods.
NICE recommends Liraglutide for treatment of obesity and non-diabetic hyperglycaemia
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
Common osteoporosis treatments could reduce incidence of COVID-19
Osteoporosis treatments including denosumab, zoledronate and calcium could protect patients against COVID-19, researchers have said.
IDMC recommends modifications to Regeneron COVID-19 antibody trial
The clinical trial testing the REGN-COV2 antibody cocktail should be altered, according to the Independent Data Monitoring Committee (IDMC).
FDA publishes list of essential medicines and medical countermeasures
The agency has compiled a list of essential medicines, medical countermeasures and critical inputs, as directed by Trump’s executive order in August.
![Artist's depiction of an ultrapotent COVID-19 vaccine candidate in which 60 pieces of a coronavirus protein (red) decorate nanoparticles (blue and white). The vaccine candidate was designed using methods developed at the UW Medicine Institute for Protein Design. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response [Credit: Ian Haydon/ UW Medicine Institute for Protein Design].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Nanoparticle-covid-19-vaccine-300x278.jpg)
![Artist's depiction of an ultrapotent COVID-19 vaccine candidate in which 60 pieces of a coronavirus protein (red) decorate nanoparticles (blue and white). The vaccine candidate was designed using methods developed at the UW Medicine Institute for Protein Design. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response [Credit: Ian Haydon/ UW Medicine Institute for Protein Design].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Nanoparticle-covid-19-vaccine.jpg)
Highly potent nanoparticle COVID-19 vaccine designed using computer
Developers suggest that the potency, stability and manufacturability of the nanoparticle vaccine candidate could enable vaccination against COVID-19 on a global scale.
![Phone with regeneron logo on it in front of blurred laboratory background [Credit: adrianosiker.com/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Regeneron-300x278.jpg)
![Phone with regeneron logo on it in front of blurred laboratory background [Credit: adrianosiker.com/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Regeneron-scaled-e1604327714270.jpg)
Regeneron named top biopharma company to work for
According to Regeneron, it has placed either first or second in the same ranking for the past ten years, making it the most highly ranked company of the decade.
EC approves Zejula (niraparib) as a monotherapy for advanced ovarian cancer
The European Commission (EC) has approved Zejula, the first PARP-inhibitor monotherapy approved in the EU for patients with advanced ovarian cancer, regardless of their biomarker status.
Takeda to supply Japan with Moderna’s COVID-19 vaccine
Takeda will import and distribute 50 million doses of the mRNA-1273 vaccine candidate under an agreement with Moderna and Government of Japan.
![Phone screen displaying PerkinElmer logo next to a laptop keyboard [Credit: rafapress / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PerkinElmer-3-300x278.jpg)
![Phone screen displaying PerkinElmer logo next to a laptop keyboard [Credit: rafapress / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PerkinElmer-3-scaled-e1604320818816.jpg)
PerkinElmer to acquire Horizon Discovery for $383 Million
PerkinElmer will expand its automated life sciences discovery and applied genomics solutions with the acquisition.
Novel non-opioid postsurgical pain implant launched
Innocoll Holdings Limited has announced the commercial launch of the XARACOLL® (bupivacaine HCI) implant, a non-opioid treatment for acute post-surgical pain for up to 24 hours in adults following open inguinal hernia repair.
